Nova Biomedical Continues International Expansion with New Subsidiary in Brazil

FOR IMMEDIATE RELEASE: September 2, 2016
Contact: info@novabio.com

Nova Biomedical Continues International Expansion with New Subsidiary in Brazil

Waltham, MA – Nova Biomedical is pleased to announce the opening of a new sales, service, manufacturing, and distribution subsidiary in Brazil. The new facility demonstrates Nova’s commitment to the Brazilian market and to supporting the strong growth of in vitro diagnostic testing in Brazil and Mercosur countries.

Located in the town of Nova Lima, a suburb of the city of Belo Horizonte in the state of Minas Gerais, Nova’s new subsidiary is designed to fully support current business and to allow for anticipated future growth. The new subsidiary provides full sales and service support, inventory warehousing and distribution, and manufacturing for Nova customers in Brazil.

With the new subsidiary, Nova brings the most advanced technology whole blood analyzers for hospital and point-of-care (POC) use to Brazil. The Stat Profile® Prime line of hospital analyzers includes the Critical Care System (CCS), Electrolyte System (ES), and Prime Plus, which all feature Prime’s innovative, no-maintenance cartridge and reagent technology that saves time and space, and reduces costs.

Prime CCS offers a comprehensive testing menu of pH, PCO2, PO2, Hct, Na, K, Cl, iCa, Glu, and Lac. Prime ES provides comprehensive electrolyte testing with Na, K, Cl, iCa, and iMg. Results are ready for both devices in only 60 seconds from 100 microliters of whole blood. Prime Plus combines blood gas, electrolyte, and metabolite testing with co-oximetry, for an extensive, 22-test menu that’s ready in only 60 seconds. The Stat Profile pHOx® Ultra analyzer provides up to 20 critical care tests from 210 microliters in only two minutes, with other partial test panels available in less than one minute.

The StatStrip® and StatSensor® line of handheld, POC meter and test strip analyzers provide rapid glucose/ketone, lactate, and creatinine results at the bedside to support clinical decision making.

“We, at Nova Biomedical, are excited to welcome our new Brazilian subsidiary to our international team and for the opportunity to continue to bring Nova’s in vitro diagnostic testing technology to this important global market,” said Ken Lumm, Senior Director, International Sales at Nova.

About Nova Biomedical
Incorporated in 1976 and based in Waltham, MA, Nova Biomedical is a world leader in the development and manufacturing of state-of-the-art, whole blood, point-of-care and critical care analyzers, as well as providing the biotechnology industry with the most advanced instruments for cell culture monitoring. Nova is one of the fastest growing in vitro diagnostic companies in the world. Nova’s biosensor technology is incorporated in products ranging from handheld meters for glucose self- and point-of-care testing to critical care whole blood analyzers designed for rapid measurement of over 20 analytes. Nova’s biotechnology-specific BioProfile line has pioneered comprehensive cell culture testing, providing over 20 critical cell culture tests with over 12 unique instrument offerings for broad range of cell culture applications. Nova employs over 1,200 people worldwide and has wholly owned subsidiaries located in Brazil, Canada, Great Britain, Spain, France, Switzerland, Germany, Italy, Japan, and Taiwan. Certified by the International Organization for Standardization, Nova has manufacturing operations located in the U.S., Taiwan, and Brazil. www.novabiomedical.com